(Q34570456)

3 August 2017

1 reference

title

Risk assessment for glucosamine and chondroitin sulfate (English)

1 reference

3 August 2017

0 references

John N Hathcock

1

1 reference

3 August 2017

Andrew Shao

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

30 August 2006

1 reference

Regulatory Toxicology and Pharmacology

3 August 2017

published in

1 reference

3 August 2017

volume

47

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

78-83

1 reference

Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

The effect of glucosamine supplementation on people experiencing regular knee pain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Glucosamine: a review of its use in the management of osteoarthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Effects of glucosamine infusion on insulin secretion and insulin action in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Glucosamine sulfate in osteoarthritis of the knee.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Glucosamine therapy for treating osteoarthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Glucosamine-induced beta-cell dysfunction: a possible involvement of glucokinase or glucose-transporter type 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

The use of glucosamine therapy in osteoarthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.07.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YRTPH.2006.07.004

1 reference

3 August 2017

1 reference